Imugene has HER-Vaxx Phase 1B Data published in prestigious clinical cancer research journal
HER-Vaxx is a B-cell peptide cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. The final PFS readout is expected within months.
Imugene Ltd’s (ASX:IMU) (OTCMKTS:IUGNF) Phase 1b clinical trial data for its B cell peptide cancer immunotherapy HER-Vaxx has been published in the prestigious American Association for Cancer Research journal Clinical Cancer Research.
The article - Clinical and immunologic responses to a B-cell epitope vaccine in HER2/neu overexpressing advanced gastric cancer patients - results from Phase 1b trial IMU.ACS.001 - is authored by Professor Dr Ursula Wiedermann from the Medical University Vienna and study investigators.
Pancreatic cancer cells de-differentiate to spawn highly aggressive tumors, study shows
A Ludwig Cancer Research study has identified a previously unrecognized mechanism by which cancer cells of a relatively benign subtype of pancreatic tumors methodically revert-or de-differentiate -to a progenitor, or immature, state of cellular development to spawn highly aggressive tumors that are capable of metastasis to the liver and lymph nodes.
The study, led by Ludwig Lausanne s Douglas Hanahan and published in
Cancer Discovery, a journal of the American Association for Cancer Research, also shows that engagement of the mechanism is associated with poorer outcomes in patients diagnosed with pancreatic neuroendocrine tumors (PanNETs). Further, its findings provide concrete evidence that such cellular de-differentiation, widely observed across cancer types, is a not merely a random consequence of cancer cells other aberrations.
email article
Seeking further reductions in smoking-related mortality and morbidity, the FDA announced it will seek a ban on menthol cigarettes and flavored cigars.
City of Hope has begun a clinical trial to evaluate a mushroom-derived substance to help prevent prostate cancer progression.
AB Science announced that a phase IIb/III trial of masitinib, which targets mast cells and macrophages, met the primary endpoint of improved progression-free survival in metastatic castration-resistant prostate cancer.
Did you hear the one about the man who got COVID-19 and then his cancer went away? (
Slate)
A third of Americans don t know basic facts about the association between sun exposure and skin cancer, according to a survey by the American Academy of Dermatology.
Imugene Ltd has HER-Vaxx Phase 1B Data published in prestigious clinical cancer research journal proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.